A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL
Autor: | Olivier Pellerin, F.M. Gómez, Dirk Arnold, Roberto Iezzi, Thomas Helmberger, Julien Taieb, Bleranda Zeka, Bruno Sangro, Hans Prenen, Robert Bauer, Philippe L. Pereira, Anders Nordlund, Thierry de Baere, Geert Maleux, Nathalie Kaufmann |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
CARCINOMA DEBIRI Colorectal cancer Irinotecan THERAPY Microsphere 03 medical and health sciences 0302 clinical medicine Quality of life Clinical endpoint medicine Humans Prospective Studies Chemoembolization Therapeutic HEPATIC METASTASES TACE Science & Technology Gastroenterology & Hepatology Hepatology business.industry General surgery Liver Neoplasms Gastroenterology medicine.disease Treatment characteristics Drug-eluting microspheres Microspheres Outcome parameter DRUG-ELUTING BEADS Research Design 030220 oncology & carcinogenesis Chemoembolization 030211 gastroenterology & hepatology Observational study CLINICAL-PRACTICE GUIDELINES Human medicine business Colorectal Neoplasms Life Sciences & Biomedicine medicine.drug |
Zdroj: | Digestive and liver disease |
ISSN: | 1878-3562 1590-8658 |
Popis: | BACKGROUND: About 70-80% of patients with colorectal liver metastases appear as ineligible for a curative treatment approach. Transarterial chemoembolisation (TACE) using irinotecan-eluting beads has emerged as a promising treatment option in cases with irresectable liver metastases. Despite being in clinical practice for years, little is known about the treatment characteristics and outcomes when used as per routine hospital practice. METHODS: Patients with hepatic metastases from colorectal cancer origin, admitted to contributing centres to receive TACE with drug-eluting LifePearl® Microspheres loaded with irinotecan, as part of their standard care, will be consecutively added to the registry. Data will be collected until the end of study, loss to follow-up or death. Primary endpoint is the characterisation of the treatment usage at the selected sites in Europe. Secondary endpoints include outcome parameters, safety and toxicity, as well as quality of life. CONCLUSION AND AIMS: This multicentre, international, prospective observational study conducted in European centres plans to collect real-life data. This data will form an evidence-base from which conclusions can be drawn on how to improve patient selection and optimise treatment protocols when treating with TACE using irinotecan-eluting microspheres. Trial registration NCT03086096. ispartof: DIGESTIVE AND LIVER DISEASE vol:52 issue:8 pages:857-861 ispartof: location:Netherlands status: published |
Databáze: | OpenAIRE |
Externí odkaz: |